Shortage of key chemical hits Bharat Biotech's Covaxin ramp-up plans

Bharat Biotech is trying to ramp up capacities of Covaxin to 12 million doses per month by July, from the current 5 million doses per month

Lab test, research, r&d, chemicals, medical research, vaccine, health, pharma
Premium

Bharat Biotech is using Kansas-based ViroVax’s adjuvant to boost the immune response to its Covaxin

Sohini Das Mumbai
With Hyderabad-based vaccine maker Bharat Biotech in the midst of ramping up its capacity for Covaxin, sources said the biotechnology company is facing challenges in procuring the adjuvant used in the vaccine.

The unsung hero of vaccines is a component called the adjuvant. It puts a ‘red flag’ on the antigenic component of the vaccine — an inactivated whole or part of a virus or bacteria — and instructs the immune system to mount a defence against that antigen whenever it is encountered.

“One of the reasons for the sluggish pace of the Covaxin production scale-up is the firm facing

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Apr 15 2021 | 2:16 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com